These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 28620891)

  • 1. Population Pharmacokinetic Modeling of Olaratumab, an Anti-PDGFRα Human Monoclonal Antibody, in Patients with Advanced and/or Metastatic Cancer.
    Mo G; Baldwin JR; Luffer-Atlas D; Ilaria RL; Conti I; Heathman M; Cronier DM
    Clin Pharmacokinet; 2018 Mar; 57(3):355-365. PubMed ID: 28620891
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial.
    Tap WD; Jones RL; Van Tine BA; Chmielowski B; Elias AD; Adkins D; Agulnik M; Cooney MM; Livingston MB; Pennock G; Hameed MR; Shah GD; Qin A; Shahir A; Cronier DM; Ilaria R; Conti I; Cosaert J; Schwartz GK
    Lancet; 2016 Jul; 388(10043):488-97. PubMed ID: 27291997
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of doxorubicin following concomitant intravenous administration of olaratumab (IMC-3G3) to patients with advanced soft tissue sarcoma.
    Villalobos VM; Mo G; Agulnik M; Pollack SM; Rushing DA; Singh A; Van Tine BA; McNaughton R; Decker RL; Zhang W; Shahir A; Cronier DM
    Cancer Med; 2020 Feb; 9(3):882-893. PubMed ID: 31821732
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of the platelet-derived growth factor receptor alpha antibody olaratumab in a panel of patient-derived soft tissue sarcoma xenografts.
    Cornillie J; Wozniak A; Van Renterghem B; Van Winkel N; Wellens J; Gebreyohannes YK; Debiec-Rychter M; Sciot R; Hompes D; Schöffski P
    BMC Cancer; 2019 Jul; 19(1):724. PubMed ID: 31331295
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized phase II study of the PDGFRα antibody olaratumab plus liposomal doxorubicin versus liposomal doxorubicin alone in patients with platinum-refractory or platinum-resistant advanced ovarian cancer.
    McGuire WP; Penson RT; Gore M; Herraez AC; Peterson P; Shahir A; Ilaria R
    BMC Cancer; 2018 Dec; 18(1):1292. PubMed ID: 30591028
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase 1 study of olaratumab plus doxorubicin in Japanese patients with advanced soft-tissue sarcoma.
    Yonemori K; Kodaira M; Satoh T; Kudo T; Takahashi S; Nakano K; Ando Y; Shimokata T; Mori J; Inoue K; Oakley GJ; Sakaguchi S; Tamura K
    Cancer Sci; 2018 Dec; 109(12):3962-3970. PubMed ID: 30353601
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Olaratumab for the treatment of advanced soft tissue sarcoma.
    Okuno SH; Maran A; Robinson SI
    Expert Rev Anticancer Ther; 2017 Oct; 17(10):883-887. PubMed ID: 28862476
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Olaratumab for advanced soft tissue sarcoma.
    Tobias A; O'brien MP; Agulnik M
    Expert Rev Clin Pharmacol; 2017 Jul; 10(7):699-705. PubMed ID: 28447475
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Olaratumab in the management of advanced soft tissue sarcoma.
    Zobniw CM; Trinh VA; Posey K; Somaiah N
    J Oncol Pharm Pract; 2019 Mar; 25(2):442-448. PubMed ID: 30032714
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Olaratumab Exerts Antitumor Activity in Preclinical Models of Pediatric Bone and Soft Tissue Tumors through Inhibition of Platelet-Derived Growth Factor Receptor α.
    Lowery CD; Blosser W; Dowless M; Knoche S; Stephens J; Li H; Surguladze D; Loizos N; Luffer-Atlas D; Oakley GJ; Guo Q; Iyer S; Rubin BP; Stancato L
    Clin Cancer Res; 2018 Feb; 24(4):847-857. PubMed ID: 29191969
    [No Abstract]   [Full Text] [Related]  

  • 11. Olaratumab: A Novel Platelet-Derived Growth Factor Receptor α-Inhibitor for Advanced Soft Tissue Sarcoma.
    Andrick BJ; Gandhi A
    Ann Pharmacother; 2017 Dec; 51(12):1090-1098. PubMed ID: 28778132
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase II study of a human anti-PDGFRα monoclonal antibody (olaratumab, IMC-3G3) in previously treated patients with metastatic gastrointestinal stromal tumors.
    Wagner AJ; Kindler H; Gelderblom H; Schöffski P; Bauer S; Hohenberger P; Kopp HG; Lopez-Martin JA; Peeters M; Reichardt P; Qin A; Nippgen J; Ilaria RL; Rutkowski P
    Ann Oncol; 2017 Mar; 28(3):541-546. PubMed ID: 28426120
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination therapy with Olaratumab/doxorubicin in advanced or metastatic soft tissue sarcoma -a single-Centre experience.
    Striefler JK; Brandes F; Baur A; Pfitzner BM; Kaul D; Rau D; Dörr A; Schmiester M; Koulaxouzidis G; Bullinger L; Märdian S; Flörcken A
    BMC Cancer; 2020 Jan; 20(1):68. PubMed ID: 31996176
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I study of olaratumab, an anti-platelet-derived growth factor receptor alpha (PDGFRα) monoclonal antibody, in patients with advanced solid tumors.
    Chiorean EG; Sweeney C; Youssoufian H; Qin A; Dontabhaktuni A; Loizos N; Nippgen J; Amato R
    Cancer Chemother Pharmacol; 2014 Mar; 73(3):595-604. PubMed ID: 24452395
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Doxorubicin Plus Olaratumab vs Doxorubicin Plus Placebo on Survival in Patients With Advanced Soft Tissue Sarcomas: The ANNOUNCE Randomized Clinical Trial.
    Tap WD; Wagner AJ; Schöffski P; Martin-Broto J; Krarup-Hansen A; Ganjoo KN; Yen CC; Abdul Razak AR; Spira A; Kawai A; Le Cesne A; Van Tine BA; Naito Y; Park SH; Fedenko A; Pápai Z; Soldatenkova V; Shahir A; Mo G; Wright J; Jones RL;
    JAMA; 2020 Apr; 323(13):1266-1276. PubMed ID: 32259228
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase 1 trial of olaratumab monotherapy and in combination with chemotherapy in pediatric patients with relapsed/refractory solid and central nervous system tumors.
    Mascarenhas L; Ogawa C; Laetsch TW; Weigel BJ; Bishop MW; Krystal J; Borinstein SC; Slotkin EK; Muscal JA; Hingorani P; Levy DE; Mo G; Shahir A; Wright J; DuBois SG
    Cancer Med; 2021 Feb; 10(3):843-856. PubMed ID: 33474828
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomised phase II study of second-line olaratumab with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer.
    Hakenberg OW; Perez-Gracia JL; Castellano D; Demkow T; Ali T; Caffo O; Heidenreich A; Schultze-Seemann W; Sautois B; Pavlik I; Qin A; Novosiadly RD; Shahir A; Ilaria R; Nippgen J
    Eur J Cancer; 2019 Jan; 107():186-195. PubMed ID: 30573277
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exposure-response relationship of olaratumab for survival outcomes and safety when combined with doxorubicin in patients with soft tissue sarcoma.
    Jones RL; Mo G; Baldwin JR; Peterson PM; Ilaria RL; Conti I; Cronier DM; Tap WD
    Cancer Chemother Pharmacol; 2019 Jan; 83(1):191-199. PubMed ID: 30406840
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Olaratumab in soft tissue sarcoma - Current status and future perspectives.
    Antoniou G; Lee ATJ; Huang PH; Jones RL
    Eur J Cancer; 2018 Mar; 92():33-39. PubMed ID: 29413687
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population pharmacokinetic analysis of patritumab, a HER3 inhibitor, in subjects with advanced non-small cell lung cancer (NSCLC) or solid tumors.
    Yoshiba S; Jansen M; Matsushima N; Chen S; Mendell J
    Cancer Chemother Pharmacol; 2016 May; 77(5):987-96. PubMed ID: 27017616
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.